Trial Profile
A Randomised, Placebo-controlled, Double-blind, 3-period crossover study to evaluate the phamacodynamics of CX-8998 in young healthy male volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Nov 2018
Price :
$35
*
At a glance
- Drugs Suvecaltamide (Primary)
- Indications Epilepsy; Essential tremor; Neuropathic pain
- Focus Pharmacodynamics; Proof of concept
- Sponsors Merck & Co
- 09 Oct 2018 Results presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
- 10 May 2018 New trial record
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology